A good shower is a simple shower, no matter what influencers recommend
'I'm kind of appalled by the shower routines,' said Dr. Olga Bunimovich, a dermatologist who teaches at the University of Pittsburgh Medical College.
The multistep processes that have inspired people to spend endless amounts of time sudsing up can harm your skin — and the environment. Dermatologists say it's all mostly unnecessary.
'Your skin is a barrier,' said Dr. Nicole Negbenebor, a dermatologic surgeon at University of Iowa Health Care. 'It's one of the biggest barriers you have. It's you in your natural elements. So you want to treat it right, and then sometimes there can be too much of a good thing.'
Here's what to know about how to take a basic shower and indicators that you've gone too far with your routine.
The basics of showeringA shower is a relatively simple routine that usually doesn't require 10 steps or a plethora of products.
A daily shower with lukewarm water and a fragrance-free hypoallergenic cleanser — followed by hydrating lotion or oil afterward — will do the trick.
Don't plan to stay in the shower too long or turn the water temperature too high — it can strip your skin of the natural oils it needs to maintain its barrier, leaving it vulnerable to dryness and irritation.
When it comes to soaps, use one meant for sensitive skin. Antibacterial soaps are popular, but experts said they dry out your skin too much for daily use. (However, they can be beneficial for people with an autoimmune skin condition called hidradenitis suppurativa, which causes painful boils and abscesses on the skin.)
Oils can be beneficial for your skin once you're damp and out of the shower, Negbenebor said. But it's important to remember that oil isn't a moisturizer, but a sealant. The water hydrates your skin, but the oil will lock in that moisture.
'It's nice to hear about skincare routines that do involve both cleansing and also providing hydration,' Dr. Lisa Akintilo, a dermatologist at NYU Langone Health, 'because that's missing in a lot of people's skin care routine.'
'Double cleansing' is unnecessar
ySome influencers suggest that a skin care routine isn't complete without exfoliation and what's called double cleansing.
The latter is typically reserved for facial skincare routines, especially when you're wearing makeup, and involves using an oil-based cleanser to break down makeup and excess oil followed by a water-based cleanser to remove any remaining residue.
Experts said you don't need to bring that practice to the full body.
'Not only do I not think that we need to double cleanse our skin … people overuse soap all the time,' Bunimovich said. 'You should not be soaping up all of your skin, period.' Instead, Bunimovich added, wash your privates and your skin folds.
Another thing that can dry out your skin is antibacterial soap. There are many claims out there that say antibacterial soap is a necessity for a regular body care routine, but experts say those soaps often have the same ingredients as regular soaps and are too drying for daily use. However, they can be beneficial for people with an autoimmune skin condition called hidradenitis suppurativa, which causes painful boils and abscesses on the skin.
Exfoliate — but not too much
Exfoliation is meant to remove dead skin cells off our body, and is good for our skin, experts said. But doing it daily could cause a mound of problems, especially if you have dry skin or skin conditions like eczema or acne.
Manual exfoliation — that is when you use a body scrub or a rougher loofah — should be done sparingly to avoid irritation.
If you see rashes on your skin after exfoliation, it may be a sign you're over doing it.
A more gentle way of exfoliating is using products that have lactic or glycolic acid, dermatologists said, but not all the time.
Save water, shorten your showerShowers account for nearly 17% of Americans' indoor water use, the Environmental Protection Agency says.
Multiple states in moderate to severe drought conditions have called for water conservation efforts this year — including taking shorter showers.
If you want to get clean and retain your natural oils, a lukewarm shower that gives you enough time to clean your body should do the trick in most cases.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
27 minutes ago
- Fox News
Physical fitness represents ‘spiritual stewardship' of God's creation, says Christian bodybuilder
Hunter Sprague, a Christian bodybuilder and fitness coach in Texas, shares how he balances his dedication to physical improvements and his commitment to his faith.
Forbes
27 minutes ago
- Forbes
UnitedHealth Stock Is Being Dumped By Wall Street—Here's Why
UnitedHealth stock is being offloaded. It just reported billions in profit. Earnings were strong. The story sounded stable. Yet the stock has been sinking. It's trading near multi-year lows, underperforming peers, and reacting poorly to every quarterly release. The market doesn't move like this for nothing. Markets often sniff out risks long before they're made official. The headlines are piling up: government investigations, operational failures, and leadership questions, but the price has already started to discount something deeper. Investors are trained to react to numbers. But when structure breaks, the numbers are often the last to go. This isn't about a soft quarter. The model itself is cracking, and the market sees it. The way UnitedHealth generates earnings, the incentives behind its vertical integration, and the regulatory heat all point to fragility that isn't captured in consensus spreadsheets. The market is whispering what many investors don't want to admit: that something is changing here. And once trust fades, the re-rating isn't temporary. It's structural. UnitedHealth Stock: Big, Profitable, Misunderstood UnitedHealth trades with a market value of about $226 billion, against $400 billion in revenue for 2024, with 2025 revenue expected to reach mid‑$445 billion to $448 billion. Size doesn't really equal a safe company; it often hides the fragility beneath. Most investors can't describe how the business works. They see adjusted EPS. They don't question the mechanics. They assume that anything producing this much cash must be built to last. But what looks durable can rot from the inside. The core of UnitedHealth's engine is vertical integration. Optum decides on care, delivers it, and pays itself. One hand washes the other, all under the same roof. It's efficient when unexamined. But regulators are finally paying attention. When the payer, provider, and data all sit in one unit, it becomes harder to separate health outcomes from billing outcomes. Investors often mistake size for insulation. But complexity cuts both ways. When that model starts to wobble, through government probes, whistleblower claims, or unexplained earnings distortions, it doesn't usually collapse overnight. It slowly leaks. This is what we are witnessing. The price action is the tell. This isn't about sentiment anymore. It's about what the market now knows; the market no longer trusts what it thought it understood. You can see it is undone. Slowly at this point. But it's picking up. UnitedHealth Is In The Crosshairs Of The Regulators The Department of Justice now runs both criminal and civil investigations into UnitedHealth's Medicare Advantage billing, officially confirmed on July 24, 2025. Washington is targeting diagnostic coding and risk adjustment practices tied to higher payouts. A process investigators say may have involved pressure, bonuses, and algorithmic recommendations to staff for certain lucrative diagnoses. At the center is Optum, UnitedHealth's massive care delivery and analytics arm, which assigns diagnoses, delivers services, and influences payer reimbursement. That vertical structure underpinned margin expansion until it became a regulatory vulnerability. Congress and CMS are now eyeing those same incentives for bundled services that may prioritize profit over care. And according to multiple reports, lawmakers are drafting reforms to Medicare Advantage to clamp down on what they see as systemic abuse. This is more than a compliance issue. If enforcement leads to fines or limits on Optum's ability to steer claims, UnitedHealth loses both margin and narrative. The company disclosed a potential settlement cost of $1.6 billion tied specifically to these investigations. For investors, this isn't a question of past performance but future structure. If Washington forces a redesign in how payer, provider, and auditor relationships operate within Optum, valuation multiples change. You won't see regulatory risk on a spreadsheet. It's not in the line items. But it's in every fund manager's head. And the market is already pricing that doubt. Earnings Vs. Trust UnitedHealth keeps beating the numbers. But the market's not cheering anymore, and that should make investors stop to think. Second‑quarter 2025 adjusted EPS came in at $4.08, while GAAP net earnings per share were about $3.74, reflecting a 9‑10% spread. This isn't a one-off. The company has leaned on adjustments for several quarters, removing charges from cyberattacks, restructuring, litigation, and 'normalizing' expense items. Each quarter it gets harder to square the adjusted reality with the actual income statement. Investors have tolerated this because the stock used to respond. Now, even beats fall flat. The post-earnings reaction in July was strong, with headline numbers, and yet shares sank over 4%. It's not the earnings they're questioning. It's the whole premise. When the market no longer trusts the adjustment logic, the premium unwinds. At some point, 'adjusted' starts sounding like wishful thinking. That's a dangerous pivot for a stock that trades on perceived consistency. The issue here is credibility. And when credibility gets questioned in a complex, vertically integrated healthcare giant with active DOJ probes and massive opacity in its internal operations, the path forward narrows quickly. UnitedHealth's numbers still impress. But the market is no longer listening to the numbers alone. It's watching what they're trying to cover. Optum: The Black Box That Powered Growth At UnitedHealth For years, Optum was UnitedHealth's crown jewel. It gave the company vertical integration that most healthcare giants could only dream of. Run the insurer. Own the doctor's office. Control the pharmacy benefit manager. Route the claims. Capture every step of the dollar. Investors praised it as genius. Until now. Optum was built for margin expansion. By combining payer and provider, UnitedHealth collapsed the value chain into itself. But that same structure is now drawing fire. Regulators are asking whether a company can truly manage care outcomes and approve and profit from the services being recommended. This questions their entire integration strategy. What used to be pitched as 'scale and efficiency' now looks like opacity. Good luck getting through an Optum report without needing aspirin halfway. It's all intentional. In a market that once rewarded complexity, investors are shifting toward simplicity and transparency. Optum is the opposite. Here's the rub: the more essential Optum is to UnitedHealth's story, the more exposed the company becomes to scrutiny. Break the chain or just shake investor faith in it and the premium vanishes. Optum was once the crown jewel. Now it's the bullseye. The Cyberattack Was A Wake-Up Call At UnitedHealth When Change Healthcare, an Optum subsidiary, was hit by a massive ransomware attack earlier this year, most investors treated it as a one-off disruption. It wasn't. It was a systemic failure that revealed how fragile UnitedHealth's infrastructure had become and how slow its leadership was to respond. The breach paralyzed billing and claims systems for weeks across the U.S. healthcare network. Providers couldn't get paid. Pharmacies stalled. Patients were caught in the middle. For a company that sells itself on reliability and integration, the collapse of a core system fully exposed them to operational risk. But the real damage was reputational. CEO Andrew Witty's delayed response and lack of transparency during the fallout shook investor confidence. For a business model that depends on centralized control, a failure of this scale felt like the opposite of control. The market didn't punish the stock immediately, but the tone shifted. Since the hack, UnitedHealth stock has lagged peers, failed to respond to buybacks, and sold off post-earnings despite beats, indicating trust erosion. In healthcare, operational execution is the product. And the cyberattack told the market what the earnings couldn't: UnitedHealth may be bigger than ever, but its foundation isn't as solid as the numbers suggest. Defensive Stocks Are No Longer Safe Havens Investors once treated UnitedHealth like a bond proxy. It was dependable, defensive, and cash-rich, perfect in a zero-rate world, but the world has moved on. And the assumptions that supported its premium are unraveling with it. But investors have moved on. Higher rates change everything. Safety no longer commands a valuation premium. If anything, it draws sharper scrutiny. Now, capital seeks efficiency and flexibility. It rotates out of perceived stability the moment cracks appear. That's exactly what's happening with UnitedHealth. It's mainly about multiples. Stocks like UnitedHealth were priced on the assumption that growth would stay steady, margins wouldn't come under pressure, and regulators would remain passive. That's no longer the case. Every part of the thesis, from Medicare Advantage economics to Optum's integration, is under review. And the old multiple doesn't hold under new conditions. At 9 to 10 times forward earnings, UnitedHealth stock is still priced for control. But what happens if growth slows, scrutiny increases, and earnings quality erodes? That multiple doesn't hold when earnings wobble and faith erodes. And that's what we're starting to see. The idea that defensive means safe no longer applies. In a world where capital costs more and scrutiny cuts deeper, structural risk matters more than past predictability. And UnitedHealth is showing investors what happens when they confuse size for safety. Market Behavior Is Telling
Wall Street Journal
27 minutes ago
- Wall Street Journal
Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
Thousands of Medicare recipients will have to wait longer to get some price relief on the expensive cancer drugs they depend on for treatment, while others might not get any reprieve at all. Two little-known provisions in the One Big Beautiful Bill Act signed by President Trump in July will delay Medicare price negotiations for some of the biggest-selling drugs in the world, including Merck's Keytruda, which is used to treat cancer and had $17.9 billion in U.S. sales in 2024. Other drugs, such as Johnson & Johnson's Darzalex, will be excluded entirely.
